At the news
? NEUTRALIMPACT 2/10 8-K filed Jun 11, 2026 at 17:19 ET
Ocugen filed an 8-K reporting results from its June 11, 2026 Annual Meeting and the formal appointment of Mohamed Genead, M.D., M.Sc., as Chief Medical Officer. All four stockholder proposals passed, including election of two Class III directors, ratification of PwC as auditor, and advisory approval of executive compensation on an annual frequency. The CMO appointment formalizes a role held on an interim basis since May 8, 2026, no material business or financial implications.
- Total of 139,628,075 shares of common stock represented at the Annual Meeting.
- Kirsten Castillo, MBA, and Satish Chandran, Ph.D. were elected as Class III directors until 2029.
- PricewaterhouseCoopers LLP ratified as independent auditor for fiscal 2026 with 136,784,245 votes for.
- Advisory say-on-pay approved with 49,968,948 for vs. 13,245,090 against (excluding broker non-votes).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access